Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0692 for chemotherapy- or ADC-induced thrombocytopenia
CTR20263774Phase 3Active
- Sponsor
- Simcere Zaiming
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing SIM0692 with Placebo (2 arms). Primary endpoint: Proportion of participants with efficacy response to SIM0692 in tumor treatment-induced thrombocytopenia. Started Oct 2026; status: active.
02
Drugs
SIM0692
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20263774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263774.